Meredith Cook Sells 400 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $61.37, for a total value of $24,548.00. Following the completion of the transaction, the vice president now owns 79,345 shares in the company, valued at $4,869,402.65. This represents a 0.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Monday, April 14th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP traded up $1.31 during midday trading on Thursday, reaching $64.66. 344,202 shares of the company's stock were exchanged, compared to its average volume of 312,205. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.98 and a current ratio of 2.66. The company's 50 day simple moving average is $64.68 and its two-hundred day simple moving average is $61.19. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $77.00. The firm has a market capitalization of $1.40 billion, a PE ratio of -50.91 and a beta of 0.55.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The business had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same quarter in the previous year, the firm earned $0.82 EPS. ANI Pharmaceuticals's quarterly revenue was up 43.4% on a year-over-year basis. Equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on ANIP. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price on the stock. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective on the stock. Wall Street Zen lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Truist Financial lifted their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research report on Monday, April 21st. Finally, HC Wainwright reissued a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $80.13.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ANIP. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of ANI Pharmaceuticals by 14.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company's stock valued at $854,000 after buying an additional 1,972 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of ANI Pharmaceuticals by 6.6% during the fourth quarter. Victory Capital Management Inc. now owns 13,777 shares of the specialty pharmaceutical company's stock valued at $762,000 after purchasing an additional 858 shares during the last quarter. US Bancorp DE lifted its holdings in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares in the last quarter. GAMMA Investing LLC boosted its position in ANI Pharmaceuticals by 17,558.4% in the 1st quarter. GAMMA Investing LLC now owns 95,002 shares of the specialty pharmaceutical company's stock valued at $6,360,000 after buying an additional 94,464 shares during the last quarter. Finally, Natixis Advisors LLC increased its stake in shares of ANI Pharmaceuticals by 2.3% in the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock valued at $1,028,000 after buying an additional 417 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.